GO Main Menu Go Main Contents Go Bottom Menu
  • Remsima™ SC is the world's first subcutaneous formulation of biosimilar infliximab developed by Celltrion. It was approved by Health Canada on January 28, 2021.

    Remsima™ SC image
    • Product Name : Remsima™ SC
    • INN : Infliximab
    • Indications : rheumatoid arthritis,polyarticular juvenile idiopathic arthritis (weighing ≥ 30 kg), psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, adult ulcerative colitis, adult and adolescent (12 to 17 years of age weighing ≥ 30 kg) hidradenitis suppurativa, psoriasis or adult and pediatric uveitis (weighing ≥ 30 kg)
    • Protein Type : Monoclonal antibody (mAb)
    • Mechanism of Action : It slows down the disease progression by neutralizing tumor necrosis factor-alpha (TNF-a), which is a common cause of autoimmune diseases.
    • Drug Approval Status : Health Canada approved

    This product description is for medical and educational purposes only.
    They are not intended to promote PR or sales campaigns.
    For more details, please consult a doctor or a medical specialist. This site is intended for all over the world.

  • Yuflyma® is a low volume/high concentration biosimilar of adalimumab developed by Celltrion. It was approved by Health Canada on December 24, 2021.

    Yuflyma® image
    • Product Name : Yuflyma®
    • INN : Adalimumab
    • Indications : rheumatoid arthritis,polyarticular juvenile idiopathic arthritis (weighing ≥ 30 kg), psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, adult ulcerative colitis, adult and adolescent (12 to 17 years of age weighing ≥ 30 kg) hidradenitis suppurativa, psoriasis or adult and pediatric uveitis (weighing ≥ 30 kg)
    • Protein Type : Monoclonal antibody (mAb)
    • Mechanism of Action : Based on both the neutralization of TNF-alpha bioactivity and the induction of apoptosis of TNF-expressing mononuclear cells.
    • Drug Approval Status :Health Canada approved

    This product description is for medical and educational purposes only.
    They are not intended to promote PR or sales campaigns.
    For more details, please consult a doctor or a medical specialist. This site is intended for all over the world.

Cookie technology helps us bring you the best possible experience when you visit this website. If you continue without changing your settings, you are agreeing to the cookies on this website. To learn more about our policy on cookies, please review our privacy policy via the link at the bottom of the page.